Press Releases

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

August 8, 2024

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

July 10, 2024

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

June 27, 2024

Oragenics, Inc. Announces Closing of Public Offering

June 26, 2024

Oragenics, Inc. Announces Pricing of Public Offering

June 25, 2024

Oragenics, Inc. Announces Proposed Public Offering

June 24, 2024

Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance

June 20, 2024

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

May 16, 2024